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ABSTRACT:  
Background and Aim:  This study developed liver outcome scores in chronic hepatitis C 
(CHC) that directly predict liver related death, hepatocellular carcinoma (HCC) and liver 
decompensation.  
Methods: 617 CHC patients were followed for a mean of six years and randomized into a 
training set (n=411) and a validation set (n=206). Clinical outcomes were determined using a 
population based data-linkage system.  
Results: In the training set, albumin, gamma-glutamyl transpeptidase (GGT), hyaluronic acid 
(HA), age and sex were in the final model to predict five year liver related death (AUROC 
0.95). Two cut points (4.0, 5.5), defined three risk groups with an incidence rate for liver 
related death of 0.1%, 2% and 13.2% respectively (p<0.001). Albumin, GGT, HA, age and 
sex were used to predict five year liver decompensation (AUROC 0.90). A cut point of 4.5 
gave a sensitivity of 94% and a specificity of 84% to predict five year decompensation and 
defined two groups with an incidence rate for decompensation of 0.2% and 5.8% respectively 
(p<0.001). Alkaline phosphatase, α2-macroglobulin, age and sex were used to predict five 
year HCC occurrence (AUROC 0.95). A cut point of 8 had a sensitivity of 90% and 
specificity of 88% to predict five year HCC occurrence and defined two groups with an 
incidence rate for HCC of 0.2% and 5.6% respectively (p<0.001). Similar results were 
obtained using the validation set.  
Conclusions:  All three liver outcome scores had excellent predictive accuracy and were able 
to stratify risk into clinical meaningful categories for CHC patients.  
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INTRODUCTION:   
Hepatitis C virus (HCV) infection affects about 180 million people worldwide and 
predisposes these patients to complications of cirrhosis, hepatocellular carcinoma and early 
death.
1
 Patients with chronic hepatitis C (CHC) had a three times higher risk of overall death 
and a 17 times higher risk of liver related death than the general population.
2,3
 However, 
identifying those CHC patients who are at higher risk of developing liver related morbidity 
and mortality is problematic. This is due to the variable natural history of HCV with its 
prolonged and predominantly asymptomatic early phase and variable later progression. 
Histopathological stage of liver fibrosis has been used to stratify risk in CHC patients, but 
liver biopsy is an invasive procedure and has problems with sampling error and risk of 
serious complications.
4-6
 
Non-invasive clinical tests are used to predict the severity of liver fibrosis and these are 
serum tests and radiological tests.
7
 Only a few of the serum fibrosis panels have been shown 
to be associated with liver related clinical outcomes.
8-13
 Transient elastography was 
significantly correlated with the development of liver decompensation, hepatocellular 
carcinoma (HCC) and death for patients with chronic liver disease.
14,15
 This data suggests that 
non-invasive methods have the potential to predict clinical outcomes.  
The potential advantages of serum liver panels that have been developed to directly predict 
clinical outcomes are that they will incorporate additional analytes that are not useful in 
predicting fibrosis but will be useful in predicting clinical end points. These additional 
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analytes may be associated with other factors such as portal hypertension, coagulopathy, 
protein synthetic dysfunction and renal failure that are known to predict liver related 
outcomes.  Disease specific models have been developed for primary biliary cirrhosis and 
primary sclerosing cholangitis.
16,17
  
The aim of this study was to develop simple serum liver outcome scores that directly predict 
the risk of liver related death, HCC and decompensation in a large group of CHC patients 
who had long term clinical follow up data available. The new liver outcome scores were 
compared with existing serum fibrosis models.  
 
METHODS:  
Patient recruitment: 
CHC patients who attended the outpatient HCV liver clinics at Sir Charles Gairdner Hospital 
from 1997 to 2012 and had a Hepascore and other routine blood tests performed were 
included. Sir Charles Gairdner Hospital is a tertiary referral centre for liver disease and the 
state liver transplantation service. CHC was defined as positive HCV RNA on two occasions 
greater than six months apart. Exclusion criteria included co-infection with hepatitis B or 
HIV; hemochromatosis, α1-antitrypsin deficiency, Wilson disease or autoimmune liver 
disease; previous liver transplantation; and episodes of liver decompensation and HCC before 
enrolment. The study was approved by the Sir Charles Gairdner Hospital Human Research 
Ethics Committee and the Western Australia Department of Health Human Research Ethics 
Committee.  
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Candidate serum markers:  
Twelve serum markers were analysed and these included: hyaluronic acid (HA), bilirubin, 
gamma-glutamyl transpeptidase (GGT), α2-macroglobulin, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), platelet count, prothrombin time, international normalized 
ratio (INR), alkaline phosphatase (ALP), creatinine and albumin. Bilirubin, AST, ALT, GGT, 
ALP and albumin were measured on an automated biochemistry analyser (Hitachi 917, 
Roche Diagnostics). HA (Wako, Germany) and α2-macroglobulin (Dako, USA) are 
performed on a fully automated chemistry analyser (Olympus AU2700, Beckman). All 
analyses were performed at a central laboratory, PathWest Laboratory Medicine, Perth. 
Hepascore was calculated as y/ (1-y); where y= exp [-4.185818 - (0.0249 * Age) + (0.7464 * 
Sex) + (1.0039 * α2-macroglobulin (g/l)) + (0.0302 * HA (ug/l)) + (0.0691 * bilirubin 
(umol/l)) - (0.0012 * GGT(IU/l))].
21
 The APRI was calculated as AST(U/L) /upper normal * 
100/platelet count (109/L).
22
 The Lok index was calculated as y/ (1-y); where y= exp [-5.56 - 
0.0089 * platelet (10
3
/mm
3
) +1.26 * AST/ALT +5.27 * INR].
23
 The FIB-4 was calculated as 
age (years) *AST (U/L) /((platelets (10
9
/L) * (ALT (U/L))
1/2
).
24
  
Clinical outcomes:  
Long term follow up of patients was obtained from the Western Australian Data Linkage Unit. 
This population-based data linkage system links health related datasets including the state 
cancer register, the state hospital morbidity database and the state mortality records.
25
 The 
Hospital Morbidity Data System has 100% coverage for hospital admissions with a record 
linkage success rate >99%.
25
 The hospital admission diagnosis and the cause of death were 
recorded using ICD 9 (before 1997) and ICD 10 (after 1997) classification codes.   
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The endpoints included: Liver related death (death from liver failure, variceal bleeding, HCC, 
liver disease was the major contributing factor) or liver transplantation; First episode of liver 
decompensation (ascites, hepatic encephalopathy, variceal bleeding, hepatorenal syndrome, 
spontaneous bacterial peritonitis); and development of HCC.  Patients were followed from 
the day of entry to each end point or the end of study.  
Statistical analysis:  
Patients were randomised into a training set and a validation set (2:1 ratio). Cox regression 
analysis was used to model survival and predict liver related death, liver decompensation and 
HCC respectively. The candidate variables for each model were those factors that had a 
significant association with each end point with p value less than 0.05 using a univariate cox 
model. Age and sex were also included in all models as they are known factors that could 
affect both survival and serum marker results. The final models were chosen using the 
backwards selection method. Harrell’s C statistic was used to evaluate the predictive ability 
of models 
26
. ROC curve analysis was also used to test the ability of the final model to predict 
the risk of each clinical meaningful time point (three, five and ten years) to develop each end 
point and cut points were defined using Youden index. The survival probability for each risk 
group within the new models was calculated using Kaplan-Meier curves and a significance 
difference was defined with the log rank test. Area under ROC curve (AUROC) was 
calculated for each of the new models and this was compared with the serum fibrosis panels 
Hepascore, APRI, FIB-4 and Lok index. The incident rate of end points were calculated and 
compared using the Z test.  
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RESULTS:  
The CHC patient population included 617 patients with all stages of liver disease as 
determined by serum fibrosis models and 60% had mild liver disease (Hepascore ≤ 0.5). 411 
patients were randomised to the training set and 206 to the validation set. Patients’ 
characteristics of the two groups are shown in Table 1 and there was no significant difference 
between the two groups. Patient follow up was for a mean of six years (range 0.1–14.1). 
There were 22 liver related deaths or liver transplantations, 23 HCC’s and 27 episodes of 
decompensation by the end of follow up. Forty seven patients had a sustained viral response 
(SVR) during follow up. These patients with SVR were included in the model development 
and validation because these patients are still at risk of developing adverse clinical outcomes 
for an unknown period of time. A sensitivity analysis that censored patients with SVR was 
performed and found no significant effect on the results.   
Training set 
Liver related death was significantly associated with HA, GGT, bilirubin, α2-macroglobulin, 
platelet count, INR, prothrombin time, AST, ALP, albumin, and creatinine. These were 
included with age and sex in the initial predictive model (Table 2). The final model was 
[Liver Outcome Score (LOS)]: LOS_death = -0.1792 * albumin (g/L) +0.0042 * GGT (U/L) 
+ 0.0041 * HA (ug/L) + 0.0377 * age + 0.4492 (if sex= male) + 8 and achieved a Harrell’s C 
statistic of 0.95 (Table 2).  The AUROC for LOS_death to predict three year, five year and 
ten year liver related death was 0.96 (95% CI, 0.91–1.00), 0.95 (95%CI, 0.90–1.00) and 0.95 
(95% CI, 0.91–0.99) respectively. The mean LOS_death value in the training set was 2.99 
(range: 0.23–9.85). A cut point of 5.5 had a sensitivity of 80.0% and specificity of 96.5% to 
predict three year liver related death.  A cut point of 4.0 had a sensitivity of 92.9% and 
specificity of 85.1% to predict ten year liver related death. Using these cut points, patients 
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were categorised into low, moderate and high risk group (< 4.0, 4.0–5.5, ≥5.5) with the 
annual incident rate of 0.1%, 2.02% and 13.2% respectively. A significant difference of liver 
related survival was found between groups (P<0.0001) (Figure 1). 
Liver decompensation was significantly associated with ten variables (HA, GGT, bilirubin, 
α2-macroglobulin, platelet count, INR, prothrombin time, AST, ALP, and albumin) and these 
were included with age and sex as candidate variables in the initial model (Table 2). The final 
model: was LOS_decompensation = 0.0031 * HA (ug/L) + 0.0030 * GGT (U/L) + 0.0562 * 
age - 0.5342 (if sex= male) - 0.1870 * albumin (g/L) + 9 and had a Harrell’s C statistic of 
0.91 (Table 2). The AUROC for LOS_decompensation to predict three year, five year and ten 
year decompensation was 0.96 (95%CI, 0.93–0.99), 0.90 (95%CI, 0.80–1.00) and 0.89 
(95%CI, 0.80–0.98) respectively. The mean LOS_decompensation value in the training set 
was 3.59 (range: 0.39–9.23). A cut point of 4.5 achieved a sensitivity of 100% and a 
specificity of 83.4% to predict three year decompensation. The same cut point achieved a 
sensitivity of 94.4% and a specificity of 83.5% to predict five year decompensation and a 
sensitivity of 85.7% and specificity of 84.2% to predict ten year decompensation. Patients 
were therefore categorised into low and high risk group of developing decompensation with 
annual incidence rate of 0.15% and 5.58% respectively (Table 3). A significant difference in 
decompensation free survival was found between these two groups (p<0.0001) (Figure 1).   
The development of HCC was significantly associated with eleven variables (HA, GGT, 
bilirubin, α2-macroglobulin, platelet count, INR, prothrombin time, AST, ALT, ALP, and 
albumin) and these were included with age and sex as candidate variables to predict HCC 
(Table 2). The final model was: LOS_HCC = 1.731 (if sex= male) + 0.0093 * ALP (U/L) + 
0.6408 * α2-macroglobulin (g/L) + 0.1350 * age - 4 had a Harrell’s C statistic of 0.95. The 
AUROC for LOS_HCC to predict three year, five year and ten year HCC development was 
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0.94 (95%CI, 0.90–0.99), 0.95 (95%CI, 0.91–0.99) and 0.93 (95%CI, 0.89–0.98) respectively. 
The mean LOS_HCC value in the training set was 5.75 (range: 0.45–12.01). A cut point of 8 
had a sensitivity of 88.9% and a specificity of 87.7% to predict three year HCC development. 
The same cut point had a sensitivity of 90.0% and specificity of 87.9% to predict five year 
HCC and a sensitivity of 80% and specificity of 88.6% to predict ten year HCC development 
and. Patients were therefore categorised into low and high risk group of developing HCC 
with annual incidence rate of 0.15% and 5.78% respectively (Table 3). A significant 
difference of HCC free survival was found between these two groups (p<0.0001) (Figure 1). 
Validation set 
Patients in the validation set were followed for a mean of six years (range 0.2–14.1). Seven 
patients had a liver related death, six had liver decompensation and seven developed HCC. In 
this group the AUROC of LOS_death to predict three year, five year and ten year liver 
related death was 0.94 (95%CI, 0.89–1.00), 0.96 (95%CI, 0.92–1.00) and 0.95 (95%CI, 0.91–
0.99) respectively. The AUROC of LOS_decompensation to predict three year, five year and 
ten year decompensation was 0.94 (95%CI, 0.85–1.00), 0.95 (95%CI, 0.85–1.00) and 0.87 
(95%CI, 0.76–0.99) respectively. The AUROC of LOS_HCC  to predict three year, five year 
and ten year HCC was 0.92 (95%CI, 0.84–1.00), 0.93 (95%CI, 0.87–1.00) and 0.94 (95%CI, 
0.90–0.99) respectively.  
Comparison with other serum models: 
The predictive ability of the LOS panel was compared with Hepascore, APRI, FIB-4 and the 
Lok index (Table 3). The LOS panel had the best ability to predict liver related death, HCC 
and liver decompensation among serum models. Individual comparison showed that 
LOS_death was significantly better than Hepascore (p=0.0009) to predict liver related death. 
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LOS_HCC was significantly better than all other serum models to predict HCC development 
(Figure 2).  
DISCUSSION:  
The development of simple serum liver panel models that are able to stratify CHC patients 
into a hierarchy of risk levels of adverse clinical outcomes is of considerable clinical 
significance. The strengths of this study were the inclusion of a large number of well 
characterized CHC patients with active infection, a broad spectrum of disease severity 
(Hepascore range: 0.02–1.0) and a long follow up time of up to 14 years. Furthermore, the 
final LOS panel was validated in a separate cohort. The LOS panel had a high accuracy to 
predict five year liver related death, liver decompensation and HCC with an AUROC of 0.95, 
0.90 and 0.95 respectively. Cut points were determined to identify patients at higher risk for 
each clinical outcome and these resulted in a high sensitivity and specificity. Using the 
defined cut points, those patients categorised in the high risk group had a significantly 
increased risk of adverse clinical outcomes, especially within the first five years of follow up. 
The low risk group had excellent survival for more than ten years. The annual incidence rate 
for high risk group for liver related death, HCC development and liver decompensation was 
13.2%, 5.58% and 5.78% respectively. These rates were significantly higher than that of the 
low or moderate risk group.  
Two previous studies re-analysed the HALT-C cohort to develop models to directly predict 
clinical outcomes. The HALT-C cohort only included CHC patients with advanced liver 
fibrosis and follow up of 3.5 years.
27,28
 The first study used an increased Child-Turcotte-Pugh 
score, decompensation, HCC and all-cause mortality as a composite endpoint and analysed 
the value of direct serum fibrosis markers. The second study excluded HCC from the 
composite endpoint and analysed simple serum markers. Neither study performed AUROC or 
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sensitivity and specificity analysis of the models. A third study developed a serum model 
(HCC-4) that included age, alpha-fetoprotein, platelet count and GGT to predict the risk of 
HCC development in CHC patients with a mean of 6.8 years follow up and the AUROC was 
0.802.
29
 However, none of these studies validated the developed serum models in a separate 
cohort.  
Few studies have evaluated the ability of serum fibrosis models to predict clinical outcomes. 
In alcoholic liver disease serum fibrosis models had a moderate ability to predict liver related 
death and in CHC they had a higher accuracy than Metavir stage to predict liver related death 
and events.
8,9
 In general serum fibrosis models have at best a moderate accuracy to predict 
liver related survival and liver complications.
10-13
 Similar results were found in this present 
study for FIB-4, APRI and the Lok index. The LOS panels had a clear advantage with their 
superior predictive ability and broad applicability for CHC patients with all grades of fibrosis 
severity. Moreover, specific models were built to predict liver related death, HCC and 
decompensation and this has allowed different serum markers to be included in each model. 
HA and GGT are well recognised serum markers associated with clinical decompensation 
and were included in the liver related death and liver decompensation LOS models. ALP and 
alpha-macroglobulin were independent predictors of HCC development and were included in 
the LOS_HCC model.  
This study’s limitations include the lack of clinical data and lifestyle information (BMI, 
smoking, alcohol consumption) therefore adverse outcomes may have been influenced by 
these confounding factors. However the outcomes were still accurately predicted by the LOS 
panels. Secondly, patient outcomes were recorded by the Western Australian Data Linkage 
Unit. Clinical follow up data such as blood test, endoscopy reports and ultrasound reports 
 
 
 
 
This article is protected by copyright. All rights reserved. 
were not available for analysis. However the quality of clinical outcome data collected by the 
unit has been validated and is highly accurate.
25
   
In summary, this study developed three LOS models to predict liver related death, liver 
decompensation and HCC respectively for chronic hepatitis C patients. The predictive ability 
of the LOS panel was better than the currently used fibrosis models. The use of the LOS 
panels will potentially improve clinical care by allowing the optimum use of expensive 
directly-acting antiviral agents before the onset of significant clinical complications.
30
 In 
addition these models would also be potentially valuable in determining the start of 
ultrasound screening for HCC and for assessing the presence of complications of portal 
hypertension. Future studies are required to validate these models in addition to the presently 
accepted clinical criteria used in CHC patients.  
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 Table 1: Patients characteristics  
Characteristics Training set  (n=411) Validation  set (n=206) P value 
Age (year) 44 (10) 43 (11) 0.366 
Gender M/F 284/127 133/73 0.256 
HA (ug/L) 77 (137) 74 (141) 0.745 
GGT (U/L) 95 (122) 87(106) 0.374 
Bilirubin (umol/L) 12 (7) 11 (16) 0.746 
α2-macroglobulin (g/L) 2.74 (1.08) 2.69 (1.03) 0.547 
Platelet count (10
9
/L) 220 (81) 224 (92) 0.557 
INR 1.0 (0.1) 1.0 (0.1) 0.676 
Creatinine (umol/L) 76.5 (1.7) 78.5 (3.01) 0.551 
prothrombin time (secs) 8.9 (1.4) 8.7 (1.3) 0.066 
ALT (U/L) 117 (101) 119 (140) 0.844 
AST (U/L) 76 (60) 78 (111) 0.723 
ALP (U/L) 85 (51) 88 (45) 0.709 
Albumin (g/L) 44 (9.5) 43 (3.9) 0.280 
Hepascore  0.48 (0.33) 0.45 (0.33) 0.343 
APRI 1.03 (1.35) 1.04 (1.60) 0.930 
Lok index 0.27 (0.21) 0.27 (0.22) 0.814 
FIB-4 2.01 (2.59) 2.02 (2.97) 0.976 
Follow up year 6.0 (3.0) 6.2 (3.1) 0.429 
Liver related death 15 (3.65%) 7 (3.40%) 0.874 
HCC 16 (3.89%) 7 (3.40%) 0.760 
decompensation 21 (5.11%) 6 (2.91%) 0.255 
Sustained viral response 29 (7.06%) 18 (8.74%) 0.552 
 
Note: Continuous variables were presented as mean (standard deviation) and categorical 
variables were presented as count (percentage). 
HA, hyaluronic acid; M, male; F, female; GGT, gamma-glutamyl transpeptidase; INR, 
international normalized ratio; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; ALP, alkaline phosphatase; HCC, hepatocellular carcinoma.  
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Table 2: Univariate and multivariate analysis to predict each end point. 
 
 Coefficient , p value 
Liver related death Decompensation Hepatocellular carcinoma 
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
HA 
0.006 
p<0.001 
0.0041 
P=0.004 
0.006 
P<0.001 
0.0031 
P=0.017 
0.005 
P<0.001 
 
GGT 
0.004 
P<0.001 
0.0042 
P<0.001 
0.003 
P<0.001 
0.030 
P=0.005 
0.003 
P<0.001 
 
Bilirubin 
0.071 
P<0.001 
 0.052 
P=0.004 
 0.068 
P<0.001 
 
α2-
macroglobulin 
0.669 
P=0.001 
 0.510 
P=0.004 
 0.904 
P<0.001 
0.6408 
P=0.007 
Platelet count 
-0.021 
P<0.001 
 -0.013 
P<0.001 
 -0.020 
P<0.001 
 
INR 
8.093 
P<0.001 
 6.255 
P<0.001 
 7.125 
P<0.001 
 
Prothrombin 
time 
0.275 
P=0.002 
 0.215 
P=0.010 
 0.287 
P<0.001 
 
ALT 
0.035 
P=0.073 
 0.0002 
P=0.915 
 0.004 
P=0.011 
 
AST 
0.012 
P<0.001 
 0.009 
P<0.001 
 0.011 
P<0.001 
 
creatinine 
0.005 
P=0.008 
 -0.007 
P=0.681 
 0.001 
P=0.857 
 
ALP 
0.009 
P<0.001 
 0.009 
P<0.001 
 0.008 
P<0.001 
0.0093 
P<0.001 
albumin 
-0.313 
P<0.001 
-0.1792 
P=0.067 
-0.333 
P<0.001 
-0.1870 
P=0.034 
-0.181 
P<0.001 
 
age 
0.104 
P<0.001 
0.0377 
P=0.148 
0.118 
P<0.001 
0.0562 
P=0.019 
0.152 
P<0.001 
0.1350 
P<0.001 
sex 
0.600 
P=0.353 
0.4492 
P=0.516 
-0.315 
P=0.484 
-0.5342 
P=0.266 
1.095 
P=0.148 
1.731 
P=0.102 
 
HA, hyaluronic acid; GGT, gamma-glutamyl transpeptidase; INR, international normalized 
ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline 
phosphatase; HCC, hepatocellular carcinoma.  
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Table 3: Comparison of the accuracy of LOS panel with other models to predict liver 
related outcomes. 
Models AUROC (95% CI) 
Liver related death Decompensation HCC 
LOS_death 0.95 (0.92-0.97) - - 
LOS_decompensation - 0.88 (0.81-0.96) - 
LOS_HCC - - 0.94 (0.90-0.97) 
Hepascore 0.87 (0.82-0.93) 0.80 (0.71-0.90) 0.84 (0.78-0.90) 
APRI 0.89 (0.84-0.94) 0.75 (0.64-0.87) 0.84 (0.75-0.92) 
FIB-4 0.92 (0.87-0.96) 0.84 (0.77-0.92) 0.87 (0.82-0.93) 
Lok index 0.86 (0.75-0.96) 0.81 (0.71-0.91) 0.80 (0.70-0.90) 
 Note: Serum models were compared using the whole cohort.  
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Figure1. Survival curves according to LOS panel. (A): Liver related survival (B): 
Decompensation free survival (C): HCC free survival.  
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Figure2. ROC curves of serum models to predict HCC development. 
 
